Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News November 11th 2011

November 11th 2011

Encapsulated pancreatic progenitors derived from human embryonic stem cells as a therapy for insulin-dependent diabetes
Prior to transplanting, cells are encapsulated in alginate to prevent the immune cells of recipient attacking the graft. The alginate capsules have pores with a molecular weight cut-off of 250 kDa. These are too small to allow entry of immune cells, but large enough for passage of nutrients and insulin (Diabetes/Metabolism Research and Reviews)

Needle-free diabetes treatment wins award
The insulin mimetic currently under development is a small molecule that mimics the effects of insulin, and is suitable for sufferers of both Type 1 and Type 2 diabetes. It is hoped replacing painful injections with a pill will help more diabetics comply with their treatment (Curtin University, Australia)

A Light and Portable Novel Device for Diabetic Retinopathy Screening
Given that the EyeScan requires minimal training to use and has excellent diagnostic accuracy in screening for diabetic retinopathy, it could be potentially utilized by the primary eye care providers to widely screen for diabetic retinopathy in the community (Clinical & Experimental Ophthalmology)

Prevalence and significance of lactic acidosis in diabetic ketoacidosis
Lactic acidosis is more common in DKA than traditionally appreciated and is not associated with increased ICU LOS or mortality. The positive correlation of lactate with glucose raises the possibility that lactic acidosis in DKA may be due not only to hypoperfusion but also to altered glucose metabolism (Journal of Critical Care)

Hypoglycemia-associated Mortality Is Not Drug-associated but Linked to Comorbidities
Drug-associated hypoglycemia was not associated with increased mortality risk in patients admitted to the general wards. The association between spontaneous hypoglycemia and mortality was eliminated after adjustment for comorbidities, suggesting that hypoglycemia may be a marker of disease burden rather than a direct cause of death (American Journal of Medicine)

The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial
In difficult-to-control older subjects with type 2 DM, duration of diabetes altered the response to intensive glucose control. Intensive therapy may reduce CV events in subjects with a duration of 15 years or less and may increase risks in those with longer duration (Journal of Diabetes and Its Complications)

Development of a minimal set of prescribing quality indicators for diabetes management on a general practice level
We showed that a minimal set of prescribing quality indicators for type 2 diabetes mellitus care should not just focus on the management of different clinical risk factors but also reflect different steps of treatment intensification (Pharmacoepidemiology and Drug Safety)

A Primer on Diabetes for the astute Podiatrist
Dr Tamler reviews diabetes as it relates to the podiatrist. Arguing that podiatric physicians are on the front lines of the diabetes epidemic, Dr Tamler discusses when and how to screen for diabetes and what to do with the results obtained therein (presentPODIATRY)

Outcome of pregnancy in type 1 diabetes mellitus (T1DMP): results from combined diabetes–obstetrical clinics in Dublin in three university teaching hospitals (1995–2006)
Pregnancy outcomes in T1DMP remain worse than in the general population despite management of T1DMP in combined obstetric/diabetes clinics in a single centre using similar management protocols (Irish Journal of Medical Science)

Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin
After nearly a decade-long partnership that achieved a number of important milestones on behalf of people living with diabetes, the companies determined it was in the best interest of all constituents to amicably terminate the collaboration (Lilly)

Categories: News Pre-2012

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Napp DiabetesAstraZenecaNovo Nordisk

Silver Sponsors

About Ascensia Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership